XARELTO®: Dosing in the treatment and reduction in the risk of recurrent deep vein thrombosis (DVT) and pulmonary embolism (PE)

DOSING FOR DVT/PE TREATMENT AND RISK REDUCTION

Tablets shown not actual size.

Renal Dose Consideration
  • Avoid using XARELTO® in patients with CrCl <30 mL/min

A CONVENIENT 30-DAY STARTER PACK FOR PATIENTS WITH DVT/PE

CrCl = creatinine clearance.

General Tags: